ICU Medical (NASDAQ:ICUI) Director Elisha Finney Sells 1,700 Shares of Company Stock

ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) Director Elisha Finney sold 1,700 shares of ICU Medical stock in a transaction on Friday, November 13th. The stock was sold at an average price of $179.00, for a total transaction of $304,300.00. Following the transaction, the director owned 4,871 shares in the company, valued at approximately $871,909. This trade represents a 25.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

ICU Medical Trading Up 1.1%

Shares of ICU Medical stock traded up $1.97 during trading on Friday, hitting $179.27. The company’s stock had a trading volume of 195,454 shares, compared to its average volume of 278,884. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.37 and a quick ratio of 1.19. ICU Medical, Inc. has a 52 week low of $113.37 and a 52 week high of $192.85. The stock has a market cap of $4.48 billion, a price-to-earnings ratio of 75.01, a price-to-earnings-growth ratio of 2.23 and a beta of 0.88. The stock has a 50-day moving average price of $163.72 and a two-hundred day moving average price of $149.91.

ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.30. ICU Medical had a return on equity of 8.40% and a net margin of 2.76%. The business had revenue of $556.22 million during the quarter, compared to analyst estimates of $552.03 million. During the same period last year, the company earned $2.03 EPS. ICU Medical’s revenue for the quarter was up 4.4% compared to the same quarter last year. Equities research analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ICUI. Weiss Ratings raised shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. KeyCorp boosted their price target on shares of ICU Medical from $187.00 to $189.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Needham & Company LLC upped their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Piper Sandler increased their price objective on shares of ICU Medical from $195.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.20.

View Our Latest Report on ICUI

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in ICU Medical during the second quarter valued at about $3,744,000. Bank of America Corp DE purchased a new stake in ICU Medical during the second quarter worth about $54,059,000. Legal & General Group Plc purchased a new stake in ICU Medical during the second quarter worth about $8,444,000. Reinhart Partners LLC. bought a new stake in ICU Medical in the second quarter worth about $46,148,000. Finally, Edgestream Partners L.P. bought a new stake in ICU Medical in the first quarter worth about $965,000. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

(Get Free Report)

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.

Read More

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.